Meet the company looking to revolutionize the medical marijuana market

Kalytera is a company developing synthetic marijuana to help repair your bones faster.

Synthetic marijuana, something that’s normally frowned upon, is set to turn the medical marijuana industry upside down in the next coming years thanks to Kalytera, a company developing a suite of non-psychoactive cannabinoids.

Cannabinoids are a class of diverse chemical compounds that act on cannabinoid receptors in cells that repress neurotransmitter release in the brain

Put simply, cannabinoids are the components of marijuana that gets you high. In other cases, it’s the component that provides some sort of medicinal benefit.

Cannabinoids

What Kalytera is trying to do is something different. They want to modify cannabinoid molecules and molecules that regulates the endogenous cannabinoid signaling system. In other words, they want to strip out all the psychoactive properties, as well as any unwanted side effects. This means they’ll be able to focus on the medicinal components that, for example, helps someone heal a bone faster.

Think about it this way: If your mother, for instance, was someone who was interested in going along the medicinal marijuana route, but found herself to stigmatized by the whole idea of medical marijuana, do you think she would want to deal with any unwanted side effects? The chances of that are highly unlikely.

But let’s take a look at some of the most common side effects most people have to say when it comes to medical marijuana:

  • Drowsiness
  • Paronia
  • Altered state of consciousness
  • Bloodshot eyes
  • Anxiousness
  • Self-conscious thoughts

This is old news though. Everyone knows this, but it’s still holding a lot of people back from venturing into medical marijuana. This is where Kalytera comes into the picture.

Their first mission: Bones!

To give us a better understanding, Seth Yakatan, CEO of Kalytera was kind enough to answer some questions for SugarNugz:

In the most simplest terms, can you explain what your team is doing over at Kalytera?

Right now, Kalytera has established a leadership position in bone health. We are developing two molecules KAL671, which is a candidate for a variety of bone disorders and KAL436, which may be used to treat bone fractures.  Though Kalytera’s mission is to develop these synthetic compounds as drug therapies, and it is also exploring natural products.

Wow, that’s amazing. How would your molecules help someone with a bone fracture? For example, would it help with pain or would it help the bone repair itself faster?

It is hoped that the molecules will help in accelerating the rate of bone healing, but making factors heal faster and stronger. These are not products which are being developed for pain, but rather to enhance bone growth.

Is there anyone else doing this?

Not with cannabinoids, synthetic cannabiods or endo cannabinoid like molecules.

I see that you’re currently testing this on animals, can you share how your how these tests have gone? And when do you think you’ll be testing this on humans? 

So far the tests have been promising and positive. We expect to be in humans by 2017.

How did the idea come to fruition?

A group of founders and leading scientific minds felt that the work of Raphael Mechoulam needed to be commercialized as a therapeutic modality.

Where does Kalytera see itself in 20 years?

Hopefully as a leader in this market with several approved and marketed products.


To learn more about Kalytera and all their research, click here.

More from Kevin Raposo

Colorado’s marijuana sales total almost 1 billion in sales for 2015

Colorado is cleaning it up when it comes to marijuana sales. Just...
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *